scholarly journals Run-to-Run Tuning of Model Predictive Control for Type 1 Diabetes Subjects: In Silico Trial

2009 ◽  
Vol 3 (5) ◽  
pp. 1091-1098 ◽  
Author(s):  
Lalo Magni ◽  
Marco Forgione ◽  
Chiara Toffanin ◽  
Chiara Dalla Man ◽  
Boris Kovatchev ◽  
...  

Background: The technological advancements in subcutaneous continuous glucose monitoring and insulin pump delivery systems have paved the way to clinical testing of artificial pancreas devices. The experience derived by clinical trials poses technological challenges to the automatic control expert, the most notable being the large interpatient and intrapatient variability and the inherent uncertainty of patient information. Methods: A new model predictive control (MPC) glucose control system is proposed. The starting point is an MPC algorithm applied in 20 type 1 diabetes mellitus (T1DM) subjects. Three main changes are introduced: individualization of the ARX model used for prediction; synthesis of the MPC law on top of the open-loop basal/bolus therapy; and a run-to-run approach for implementing day-by-day tuning of the algorithm. In order to individualize the ARX model, a sufficiently exciting insulin profile is imposed by splitting the premeal bolus into two smaller boluses (40% and 60%) injected 30 min before and 30 min after the meal. Results: The proposed algorithm was tested on 100 virtual subjects extracted from an in silico T1DM population. The trial simulates 44 consecutive days, during which the patient receives breakfast, lunch, and dinner each day. For 10 days, meals are multiplied by a random variable uniformly distributed in [0.5, 1.5], while insulin delivery is based on nominal meals. Moreover, for 10 days, either a linear increase or decrease of insulin sensitivity (±25% of nominal value) is introduced. Conclusions: The ARX model identification procedure offers an automatic tool for patient model individualization. The run-to-run approach is an effective way to auto-tune the aggressiveness of the closed-loop control law, is robust to meal variation, and is also capable of adapting the regulator to slow parameter variations, e.g., on insulin sensitivity.

2008 ◽  
Vol 41 (2) ◽  
pp. 4246-4251 ◽  
Author(s):  
L. Magni ◽  
D.M. Raimondo ◽  
C. Dalla Man ◽  
G. De Nicolao ◽  
B. Kovatchev ◽  
...  

2007 ◽  
Vol 1 (6) ◽  
pp. 804-812 ◽  
Author(s):  
Lalo Magni ◽  
Davide M. Raimondo ◽  
Luca Bossi ◽  
Chiara Dalla Man ◽  
Giuseppe De Nicolao ◽  
...  

2018 ◽  
Vol 12 (2) ◽  
pp. 273-281 ◽  
Author(s):  
Roberto Visentin ◽  
Enrique Campos-Náñez ◽  
Michele Schiavon ◽  
Dayu Lv ◽  
Martina Vettoretti ◽  
...  

Background: A new version of the UVA/Padova Type 1 Diabetes (T1D) Simulator is presented which provides a more realistic testing scenario. The upgrades to the previous simulator, which was accepted by the Food and Drug Administration in 2013, are described. Method: Intraday variability of insulin sensitivity (SI) has been modeled, based on clinical T1D data, accounting for both intra- and intersubject variability of daily SI. Thus, time-varying distributions of both subject’s basal insulin infusion and insulin-to-carbohydrate ratio were calculated and made available to the user. A model of “dawn” phenomenon based on clinical T1D data has been also included. Moreover, the model of subcutaneous insulin delivery has been updated with a recently developed model of commercially available fast-acting insulin analogs. Models of both intradermal and inhaled insulin pharmacokinetics have been included. Finally, new models of error affecting continuous glucose monitoring and self-monitoring of blood glucose devices have been added. Results: One hundred in silico adults, adolescent, and children have been generated according to the above modifications. The new simulator reproduces the intraday glucose variability observed in clinical data, also describing the nocturnal glucose increase, and the simulated insulin profiles reflect real life data. Conclusions: The new modifications introduced in the T1D simulator allow to extend its domain of validity from “single-meal” to “single-day” scenarios, thus enabling a more realistic framework for in silico testing of advanced diabetes technologies including glucose sensors, new insulin molecules and artificial pancreas.


2010 ◽  
Vol 43 (14) ◽  
pp. 1052-1057 ◽  
Author(s):  
Dimitri Boiroux ◽  
Daniel A. Finan ◽  
John Bagterp Jørgensen ◽  
Niels Kjølstad Poulsen ◽  
Henrik Madsen

Sign in / Sign up

Export Citation Format

Share Document